2 not yet recruiting, 2 recruiting, 1 completed, 1 unknown. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Not yet recruiting 2, Recruiting 2, Completed 1, Unknown 1 |
Follow T2DM (Type 2 Diabetes Mellitus): new trials by email Literature Review of T2DM (Type 2 Diabetes Mellitus) trials Research Report on T2DM (Type 2 Diabetes Mellitus)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease Dulaglutide, SGLT2i, Finerenone - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2026-05-01 | 2026-04-22 |
| Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease ganagliflozin, Placebo - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 1244 | 2025-11-30 | 2025-11-18 |
| GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM semaglutide, Standard Treatment (Guideline-Based) - T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Federico II University | 80 | 2025-09-08 | 2026-01-02 |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin - T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 430 | 2025-03-29 | 2025-11-24 |
| RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD Dabigatran Etexilate - Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Unknown | Irina Ermolaeva | 200 | 2018-11-14 | 2021-03-26 |
| SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study) Empagliflozin, Placebo - Nocturnal Hypertension, T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Completed | Jichi Medical University | 174 | 2017-01-01 | 2018-03-27 |
Diabetes Mellitus, Type 2 (6) · Renal Insufficiency, Chronic (3) · Atrial Fibrillation (1) · Inflammation (1)
Diabetes Mellitus (6) · Endocrine System Diseases (6) · Glucose Metabolism Disorders (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Disease Attributes (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Renal Insufficiency (3) · Urogenital Diseases (3)
Dabigatran (1) · Liraglutide (1) · Metformin (1) · dulaglutide (1) · empagliflozin (1) · finerenone (1) · semaglutide (1)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (2) · Federico II University (1) · First Affiliated Hospital of Wannan Medical College (1) · Irina Ermolaeva (1) · Jichi Medical University (1)
China (2) · Italy (1) · Japan (1) · Russia (1)
Dmitry Napalkov (1) · Kazuomi Kario, MD (1)
2025 (1)